The evERA study showed significant PFS improvements with giredestrant plus everolimus in ER-positive, HER2-negative breast ...

The TROPION-Breast02 trial is the first to show overall survival benefit in this patient population, indicating a potential ...

Patients receiving ribociclib 400 mg had a shorter QTcF (12.5 vs 19.7 ms at cycle 1 day 15, 2 hours post-dose) and a lower ...

October 2025 Datroway demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer ...

In HR+/HER- early breast cancer, the DFS benefits of adjuvant ribociclib plus NSAI treatment compared to NSAI alone persisted even a year after treatment completion.

In September 2025, the U.S. Food and Drug Administration (FDA) approved several new cancer therapies and supportive care ...

The U.S. Food and Drug Administration (FDA) has granted priority review and breakthrough therapy designation to the ...

Read on to explore why Black women are facing a higher mortality rate from breast cancer and what’s being done to combat it.

The FDA has approved Eli Lilly’s imlunestrant, an oral estrogen receptor antagonist, for the treatment of adults with ...

Enhertu plus pertuzumab granted Priority Review in US as 1st-line treatment for patients with HER2-positive metastatic breast cancer: Cambridge, UK Thursday, September 25, 2025, 0 ...

In breast cancer patients with a high recurrence score, the 5-year disease-free rate was significantly higher for patients receiving taxanes with anthracycline and cyclophosphamide than for those ...

Roche announces positive results from phase III evERA study of giredestrant in combo with everolimus in ER-positive advanced breast cancer: Basel Tuesday, September 23, 2025, 15:0 ...